Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Angiogenesis-related gene expression profile with independent prognostic value in advanced ovarian carcinoma.

Mendiola M, Barriuso J, Redondo A, Mariño-Enríquez A, Madero R, Espinosa E, Vara JA, Sánchez-Navarro I, Hernández-Cortes G, Zamora P, Pérez-Fernández E, Miguel-Martín M, Suárez A, Palacios J, González-Barón M, Hardisson D.

PLoS One. 2008;3(12):e4051. doi: 10.1371/journal.pone.0004051. Epub 2008 Dec 29.

2.

The miR-200 family controls beta-tubulin III expression and is associated with paclitaxel-based treatment response and progression-free survival in ovarian cancer patients.

Leskelä S, Leandro-García LJ, Mendiola M, Barriuso J, Inglada-Pérez L, Muñoz I, Martínez-Delgado B, Redondo A, de Santiago J, Robledo M, Hardisson D, Rodríguez-Antona C.

Endocr Relat Cancer. 2010 Dec 21;18(1):85-95. doi: 10.1677/ERC-10-0148. Print 2011 Feb.

3.

Unique gene expression profile based on pathologic response in epithelial ovarian cancer.

Spentzos D, Levine DA, Kolia S, Otu H, Boyd J, Libermann TA, Cannistra SA.

J Clin Oncol. 2005 Nov 1;23(31):7911-8. Epub 2005 Oct 3.

PMID:
16204010
4.

Prognostic significance of Hypoxia-Inducible Factor 1 alpha(HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study.

Daponte A, Ioannou M, Mylonis I, Simos G, Minas M, Messinis IE, Koukoulis G.

BMC Cancer. 2008 Nov 16;8:335. doi: 10.1186/1471-2407-8-335.

5.

A seven-gene prognostic model for platinum-treated ovarian carcinomas.

Sabatier R, Finetti P, Bonensea J, Jacquemier J, Adelaide J, Lambaudie E, Viens P, Birnbaum D, Bertucci F.

Br J Cancer. 2011 Jul 12;105(2):304-11. doi: 10.1038/bjc.2011.219. Epub 2011 Jun 7.

6.

Survival-related profile, pathways, and transcription factors in ovarian cancer.

Crijns AP, Fehrmann RS, de Jong S, Gerbens F, Meersma GJ, Klip HG, Hollema H, Hofstra RM, te Meerman GJ, de Vries EG, van der Zee AG.

PLoS Med. 2009 Feb 3;6(2):e24. doi: 10.1371/journal.pmed.1000024.

7.

Preoperative serum tissue factor levels are an independent prognostic factor in patients with ovarian carcinoma.

Han LY, Landen CN Jr, Kamat AA, Lopez A, Bender DP, Mueller P, Schmandt R, Gershenson DM, Sood AK.

J Clin Oncol. 2006 Feb 10;24(5):755-61. Epub 2005 Dec 27.

PMID:
16380413
8.

A prognostic gene expression index in ovarian cancer - validation across different independent data sets.

Denkert C, Budczies J, Darb-Esfahani S, Györffy B, Sehouli J, Könsgen D, Zeillinger R, Weichert W, Noske A, Buckendahl AC, Müller BM, Dietel M, Lage H.

J Pathol. 2009 Jun;218(2):273-80. doi: 10.1002/path.2547.

PMID:
19294737
9.

Gene expression profiles as prognostic markers in women with ovarian cancer.

Jochumsen KM, Tan Q, Høgdall EV, Høgdall C, Kjaer SK, Blaakaer J, Kruse TA, Mogensen O.

Int J Gynecol Cancer. 2009 Oct;19(7):1205-13. doi: 10.1111/IGC.0b013e3181a3cf55.

PMID:
19823056
10.

Expression of the angopoietin-1, angopoietin-2, Tie2, and vascular endothelial growth factor gene in epithelial ovarian cancer.

Hata K, Nakayama K, Fujiwaki R, Katabuchi H, Okamura H, Miyazaki K.

Gynecol Oncol. 2004 Apr;93(1):215-22.

PMID:
15047239
11.

Prognostic value of DNA quantification in early epithelial ovarian carcinoma.

Valverde JJ, Martin M, García-Asenjo JA, Casado A, Vidart JA, Díaz-Rubio E.

Obstet Gynecol. 2001 Mar;97(3):409-16.

PMID:
11239647
12.

Effect of adjuvant paclitaxel and carboplatin for advanced stage epithelial ovarian cancer: a population-based cohort study of all patients in western Sweden with long-term follow-up.

Akeson M, Zetterqvist BM, Dahllöf K, Brännström M, Horvath G.

Acta Obstet Gynecol Scand. 2008;87(12):1343-52. doi: 10.1080/00016340802495491.

PMID:
18951208
13.

Optimal chemotherapy treatment for women with recurrent ovarian cancer.

Fung-Kee-Fung M, Oliver T, Elit L, Oza A, Hirte HW, Bryson P.

Curr Oncol. 2007 Oct;14(5):195-208.

14.

Subcellular localization of activated leukocyte cell adhesion molecule is a molecular predictor of survival in ovarian carcinoma patients.

Mezzanzanica D, Fabbi M, Bagnoli M, Staurengo S, Losa M, Balladore E, Alberti P, Lusa L, Ditto A, Ferrini S, Pierotti MA, Barbareschi M, Pilotti S, Canevari S.

Clin Cancer Res. 2008 Mar 15;14(6):1726-33. doi: 10.1158/1078-0432.CCR-07-0428.

15.

Steroid hormone regulation and prognostic value of the human kallikrein gene 14 in ovarian cancer.

Yousef GM, Fracchioli S, Scorilas A, Borgoño CA, Iskander L, Puopolo M, Massobrio M, Diamandis EP, Katsaros D.

Am J Clin Pathol. 2003 Mar;119(3):346-55.

PMID:
12645335
16.

WT1 gene expression as a prognostic marker in advanced serous epithelial ovarian carcinoma: an immunohistochemical study.

Netinatsunthorn W, Hanprasertpong J, Dechsukhum C, Leetanaporn R, Geater A.

BMC Cancer. 2006 Apr 11;6:90.

17.

p53 and bcl-2 in epithelial ovarian carcinoma: their value as prognostic indicators at a median follow-up of 60 months.

Geisler JP, Geisler HE, Miller GA, Wiemann MC, Zhou Z, Crabtree W.

Gynecol Oncol. 2000 May;77(2):278-82.

PMID:
10785478
18.

Intratumoral microvessel density, response to chemotherapy and clinical outcome of patients with advanced ovarian carcinoma.

Gadducci A, Viacava P, Cosio S, Fanelli G, Fanucchi A, Cecchetti D, Cristofani R, Genazzani AR.

Anticancer Res. 2003 Jan-Feb;23(1B):549-56.

PMID:
12680144
19.

Vascular endothelial growth factor expression in early stage ovarian carcinoma.

Paley PJ, Staskus KA, Gebhard K, Mohanraj D, Twiggs LB, Carson LF, Ramakrishnan S.

Cancer. 1997 Jul 1;80(1):98-106.

PMID:
9210714
20.

Topoisomerase IIalpha mRNA and protein expression in ovarian carcinoma: correlation with clinicopathological factors and prognosis.

Faggad A, Darb-Esfahani S, Wirtz R, Sinn B, Sehouli J, Könsgen D, Lage H, Weichert W, Noske A, Budczies J, Müller BM, Buckendahl AC, Röske A, Eldin Elwali N, Dietel M, Denkert C.

Mod Pathol. 2009 Apr;22(4):579-88. doi: 10.1038/modpathol.2009.14. Epub 2009 Mar 6.

Supplemental Content

Support Center